

Medicines and Healthcare products Regulatory Agency

MANUFACTURER'S AUTHORISATION

1: Authorisation Number	UK MIA(IMP) 3473
2: Name of authorisation holder	NHS NATIONAL SERVICES SCOTLAND NHS NATIONAL SERVICES SCOTLAND, THE JACK COPLAND CENTRE, 52 RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK, RICcarton, CURRIE, EH14 4BE, UNITED KINGDOM
3: Address(es) of manufacturing site(s)	INSTITUTE FOR REGENERATION AND REPAIR - NORTH, GMP CELLULAR THERAPY FACILITY, SCOTTISH CENTRE FOR REGENERATIVE MEDICINE, EDINBURGH BIOQUARTER, 5 LITTLE FRANCE DRIVE, EDINBURGH, EH16 4UU, UNITED KINGDOM
4: Legally registered address of authorisation holder	NHS NATIONAL SERVICES SCOTLAND, THE JACK COPLAND CENTRE, 52 RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK, RICcarton, CURRIE, EH14 4BE, UNITED KINGDOM
5: Scope of authorisation and dosage forms	ANNEX 1 and/ or ANNEX 2
6: Legal Basis of authorisation	Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031]
7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation	Confidential
8: Authorisation Date	07/01/2025
9: Annexes attached	Annex 1 and/or Annex 2

SCOPE OF AUTHORISATION

Annex 2

Name and address of the site:

NHS NATIONAL SERVICES SCOTLAND, THE JACK COPLAND CENTRE, 52 RESEARCH AVENUE NORTH, HERIOT-WATT RESEARCH PARK, RICcarton, CURRIE, EH14 4BE, UNITED KINGDOM

Human Investigational Medicinal Products
Authorised Operations
MANUFACTURING OPERATIONS (according to part 1)
Part 1 - MANUFACTURING OPERATIONS [1.1] Sterile Investigational Medicinal Products [1.1.1] Aseptically prepared (processing operations for the following dosage forms)

- [1.1.1.6] Other aseptically prepared products
Human derived ATMPs as stipulated in 1394/2007. Cell banking of cells of human origin.

[1.3] Biological investigational medicinal products

- [1.3.1] Biological medicinal products
 - [1.3.1.3] Cell therapy products
 - [1.3.1.4] Gene therapy products
 - [1.3.1.8] Other biological medicinal products
Human derived ATMPs as stipulated in 1394/2007. Cell banking of cells of human origin.

[1.5] Packaging

- [1.5.1] Primary packaging
 - [1.5.1.6] Liquids for internal use
- [1.5.2] Secondary packaging

[1.6] Quality control testing

- [1.6.2] Microbiological: non-sterility
- [1.6.3] Chemical/Physical
- [1.6.4] Biological

SCOPE OF AUTHORISATION

Annex 2

Name and address of the site:

INSTITUTE FOR REGENERATION AND REPAIR - NORTH, GMP CELLULAR THERAPY FACILITY, SCOTTISH CENTRE FOR REGENERATIVE MEDICINE, EDINBURGH BIOQUARTER, 5 LITTLE FRANCE DRIVE, EDINBURGH, EH16 4UU, UNITED KINGDOM

Human Investigational Medicinal Products
Authorised Operations
MANUFACTURING OPERATIONS (according to part 1)

Part 1 - MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

- [1.1.1] Aseptically prepared (processing operations for the following dosage forms)
 - [1.1.1.6] Other aseptically prepared products
Human derived ATMPs as stipulated in 1394/2007

[1.3] Biological investigational medicinal products

- [1.3.1] Biological medicinal products
 - [1.3.1.3] Cell therapy products
 - [1.3.1.4] Gene therapy products
 - [1.3.1.6] Human or animal extracted products
 - [1.3.1.8] Other biological medicinal products
Cell banking of cells of human origin

[1.5] Packaging

- [1.5.1] Primary packaging
 - [1.5.1.6] Liquids for internal use

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.2] Microbiological: non-sterility

[1.6.3] Chemical/Physical

[1.6.4] Biological

MHRA-GMDP

MHRA

MHRA-GMDP

MHRA